Prolia (denosumab) 60 mg, in syringe, Amgen, USA

Indications

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women, Prolia® significantly reduces the risk of vertebral fractures, non-vertebral fractures, and hip fractures.

Treatment of bone loss in men at increased risk of fractures receiving hormone-suppressive therapy for prostate cancer (see Pharmacodynamics). In men with prostate cancer receiving hormone-suppressive therapy, Prolia® significantly reduces the risk of vertebral fractures.

 Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture

Dosage

The recommended dose of denosumab is one subcutaneous injection of 60 mg of the drug once every 6 months, administered in the thigh, abdomen, or outer upper arm.